New publication shows glasmacinal reduces eosinophilic airway inflammation in preclinical models

REYKJAVIK, ICELAND – 24 March 2026 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral anti-inflammatory drugs for the treatment of COPD, has published its latest research article in the peer-reviewed journal Lung.

The publication, entitled “The effect of the novel macrolide glasmacinal (EP395) on allergen-induced eosinophil infiltration into the lung”, was authored by EpiEndo’s Dr Jennifer Kricker (Head of Research), Dr Ginny Norris (CMO), and Prof. Michael Parnham (Senior Advisor), together with collaborators from King’s College London, Prof Clive Page and Dr Yanira Riffo-Vasquez. The article shows that glasmacinal reduces eosinophilic inflammation in two established preclinical models of allergic airway disease. Treatment with glasmacinal was shown to reduce key inflammatory markers, both locally in the lung and systemically, and to reduce inflammation-associated airway remodelling, demonstrating broad anti-inflammatory and protective epithelial effects.

These findings, together with previous data that glasmacinal reduces neutrophilic inflammation in both preclinical models and in patients with COPD (Kricker J et al. 2025. Pulm. Pharmacol. Ther.; Watz, H. et al. 2025. ERJ Open Res.), support its potential as a new therapeutic option for patients with COPD who continue to exacerbate on top of standard of care, regardless of the type of inflammation. It also suggests the potential use of glasmacinal for the treatment of asthma.

Dr Jennifer Kricker, Head of Research at EpiEndo Pharmaceuticals commented:

“The new data showing effects on eosinophilic inflammation, alongside previously demonstrated effects on neutrophilic inflammation, further positions glasmacinal as a drug with the potential to impact current standard-of-care for both COPD and asthma.”

Prof Clive Page, Emeritus Professor of Pharmacology at King’s College London and Chairman of the SAB for EpiEndo commented:

“The evidence base continues to build that glasmacinal has broad anti-inflammatory activity supporting its use as a novel, first in class drug for the treatment of patients with respiratory disease.”